VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxart, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Vaxart, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Government Contract [Member] | $24.26M | $36.37M | $93.08M | $72.41M | $39.73M | $19.30M | $12.01M | $4.89M | $6.36M | $1.60M | $0 | $0 | 89.2% | -38.9% |
| Collaboration Revenue [Member] | $2.92M | $2.82M | – | – | $0 | $0 | – | – | – | – | – | – | 10.7% | – |
| Non Cash Royalty Revenue [Member] | $11.00K | $42.00K | $350.00K | $0 | $0 | $1.58M | $3.18M | $40.00K | $37.00K | $585.00K | $3.17M | $446.00K | 0.0% | – |
| Grant [Member] | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $79.00K | $1.66M | – | – |
By region
From the segment and revenue-disaggregation notes of Vaxart's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.